ASH 2025 Frontiers Flash: How MRD Redefines the New Standard for Lymphoma Cure? | Precision Medicine Insights Episode 32
Juventas
Innovative Cell Therapy Drug Developer
The 67th American Society of Hematology (ASH) Annual Meeting, which has just concluded, once again demonstrated that lymphoma treatment has entered a precision model guided by minimal residual disease (MRD). From long-term follow-ups of CAR-T to combination strategies involving bispecific antibody drugs and antibody-drug conjugates (ADCs), MRD is not only the "gold standard" for evaluating deep remission but also the core decision-making basis for guiding treatment de-escalation, intensification, or intervention. MRD negativity is transitioning from a research endpoint to a new definition of clinical cure. However, challenges and opportunities coexist: How can technology be standardized? How can clinical pathways be implemented? How can biopharmaceutical companies leverage MRD to accelerate product approval?
On December 16 at 19:00, at the very first moment when the ASH hotspot began to emerge, Episode 32 of "MedPrecision" invited four industry and technology experts working on the front lines. In conjunction with the latest trends from ASH, they systematically deconstructed for you:Lymphoma Diagnosis and Treatment Innovation Driven by MRD`, Invited`Yi Feng, Senior Vice President of Juventas、Chen Xiangmei, Senior Expert in Clinical Biomarkers at Zhejiang Borui Biopharmaceutical Co., Ltd.、Cao Dandan, Director of Product and Transformation at Genetron HealthAndGeorge Zhao, Deputy Director of BD at Genetron HealthFour top technology and management experts will systematically analyze how MRD leads this profound revolution in lymphoma diagnosis and treatment from three dimensions: technological evolution, drug development, and clinical implementation.
December 16, 2025 (Tuesday) 19:00-20:30, we will meet online! Scan the QR code below to sign up and join us!
Welcome to scan the QR code or click the linkWatch
Scan the code to watch the live stream
Join the group to participate in the discussion
?PC端观看路径（Copy to webpage to open）
https://cast.263live.net/o106G8
Guest Information
Yi Feng
Juventas
Senior Vice President of Medicine
Graduated from Peking Union Medical College, has been engaged in new drug research and development work in multinational pharmaceutical enterprises (Roche, Novartis, etc.) and innovative pharmaceutical enterprises (Juventas, Lingmed). Currently serving as Senior Vice President at Juventas Biotechnology Co., Ltd., overseeing functional departments including Clinical Medicine, Translational Medicine, Pharmacovigilance, Quality Assurance, and Medical Writing. Focuses on oncology, cardiovascular and metabolic diseases, autoimmune diseases, nephrology, neuropsychiatric disorders, etc.; possesses extensive experience in the new drug development of hematological malignancies and solid tumors. Responsible for critical registration clinical trials in China, Asia-Pacific, and globally. The R&D portfolio includes small molecule drugs, large molecule drugs, antibody-drug conjugates (ADCs), immunotherapy drugs, bispecific antibodies, and cell therapy products (CAR-T), among others.
Chen Xiangmei
Zhejiang Borui Biopharmaceutical Co., Ltd.
Senior Expert in Clinical Biomarkers
PhD graduated from Rutgers/New Jersey Medical University in the United States, and completed postdoctoral studies at the University of Pennsylvania. With over 8 years of experience in biomarker research for new drug development, has led multiple international multicenter clinical biomarker studies and CDx development projects across various stages from Pre-IND to FIH and NDA filing while working at Sanofi, Haihe BioPharma, and BeiGene. These projects spanned several disease areas including metabolic diseases, solid tumors, and hematological malignancies, with findings presented at internationally renowned clinical conferences. Currently leading multiple FIH ADC biomarker clinical studies and CDx development projects.
Cao Dandan
Genetron Health
Director of Product and Transformation
Director of Product and Translation, Senior Engineer at Beijing Genetron Health Technology Co., Ltd., mainly responsible for clinical research design, implementation and quality control management, academic promotion, achievement transformation, and the development and application of innovative technologies related to molecular diagnostics.
Doctorate degree from the Beijing Institute of Genomics, Chinese Academy of Sciences, majoring in genomics. Accumulated extensive R&D experience in cancer gene testing, genomics and transcriptomics, and biotechnology research. Participated as a key member in multiple National Natural Science Foundation of China projects and National Key R&D Program projects. Contributed to the writing of "Genomics and Precision Medicine" in the "Fundamentals of Precision Medicine Series." Engaged in cancer genomics research for over a decade, with research areas covering the application of genomics-related technologies, including studies on genomic characteristics of gliomas and colorectal cancer. Relevant research findings have been published in international journals such as Molecular Cancer, npj Precision Oncology, Frontier of Medicine, and Frontiers in Pharmacology. Holds two authorized patents and has abundant experience in clinical research and achievement transformation.
Hongwei Zhao
Genetron Health
BD Vice Director
Hao Wei Zhao, Deputy Director of BD at Genetron Health, mainly responsible for formulating solutions and overseeing large projects related to molecular testing and companion diagnostics for clinical trials of new drugs in solid tumors and hematological cancers. With nearly twelve years of relevant work experience in the field of molecular diagnostics, he has successively engaged in bioinformatics and product development in areas such as genomics, transcriptomics, resequencing, and molecular testing of hematological malignancies. He has participated in several major national-level scientific research projects, with related achievements published as the first author in top international core journals such as Nature Communications and Nature Genetics. He has also been granted more than 10 authorized invention patents and software copyrights.
Medicine Precision｜Previous Playback
Scan the QR code to watch all the content of the [Medicine Precision] series live broadcast.
